Upregulation of long non-coding RNA TUG1 correlates with poor prognosis and disease status in osteosarcoma

Tumor Biology

Volumn 37, Issue 4, 2016, Pages 4445-4455

  Ma, Bing ^a   Li, Meng ^b   Zhang, Lei ^c   Huang, Ming ^a   Lei, Jun Bin ^a   Fu, Gui Hong ^d   Liu, Chun Xin ^e   Lai, Qi Wen ^f   Chen, Qing Quan ^g   Wang, Yi Lian ^h  

^a The Third People's Hospital of Bengbu   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

^c Peoples Hospital of Lanxi City   (China)

^d Guizhou Province Osteological Hospital   (China)

^e Jianou Municipal Hospital   (China)

^f Dehua County Hospital   (China)

^g FUZHOU GENERAL HOSPITAL   (China)

^h Departments of Ultrasound Lianyungang Second Hospital   (China)

Author keywords

lncRNA; Osteosarcoma; Prognosis; TUG1

Indexed keywords

LONG UNTRANSLATED RNA; ALKALINE PHOSPHATASE; TUG1 LONG NONCODING RNA, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUG1 GENE; TUMOR VOLUME; UPREGULATION; ADOLESCENT; AREA UNDER THE CURVE; BLOOD; BONE NEOPLASMS; CASE CONTROL STUDY; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE; AREA UNDER CURVE; BIOMARKERS, TUMOR; BONE NEOPLASMS; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOSARCOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA, LONG NONCODING; ROC CURVE; UP-REGULATION; YOUNG ADULT;

EID: 84945161665     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4301-6     Document Type: Article

References (36)

1. Bielack S, Carrle D, Casali PG. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 Suppl 4:137–9. doi:10.1093/annonc/mdp154.
2. Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing’s sarcoma: national cancer data base report. Clin Orthop Relat Res. 2007;459:40–7. doi:10.1097/BLO.0b013e318059b8c9.
3. Stark A, Kreicbergs A, Nilsonne U, Silfversward C. The age of osteosarcoma patients is increasing. An epidemiological study of osteosarcoma in Sweden 1971 to 1984. J Bone Joint Surg (Br). 1990;72(1):89–93.
4. Grimer RJ, Cannon SR, Taminiau AM, Bielack S, Kempf-Bielack B, Windhager R, et al. Osteosarcoma over the age of forty. Eur J Cancer. 2003;39(2):157–63.
5. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20(3):776–90.
6. Hammond SM. MicroRNAs as oncogenes. Curr Opin Genet Dev. 2006;16(1):4–9. doi:10.1016/j.gde.2005.12.005.
7. Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–69. doi:10.1038/nrc1840.
8. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464(7291):1071–6. doi:10.1038/nature08975.
9. Deng Q, He B, Gao T, Pan Y, Sun H, Xu Y, et al. Up-regulation of 91H promotes tumor metastasis and predicts poor prognosis for patients with colorectal cancer. PLoS ONE. 2014;9(7):e103022. doi:10.1371/journal.pone.0103022.
10. Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet. 2013;45(11):1392–8. doi:10.1038/ng.2771.
11. Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology. 2007;132(1):330–42. doi:10.1053/j.gastro.2006.08.026.
12. Arita T, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Shoda K, et al. Circulating long non-coding RNAs in plasma of patients with gastric cancer. Anticancer Res. 2013;33(8):3185–93.
13. Tinzl M, Marberger M, Horvath S, Chypre C. DD3 PCA3 RNA analysis in urine—a new perspective for detecting prostate cancer. Eur Urol. 2004;46(2):182–6. doi:10.1016/j.eururo.2004.06.004. discussion 7.
14. Qi P, Du X. The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol. 2013;26(2):155–65. doi:10.1038/modpathol.2012.160.
15. Young TL, Matsuda T, Cepko CL. The noncoding RNA taurine upregulated gene 1 is required for differentiation of the murine retina. Curr Biol. 2005;15(6):501–12. doi:10.1016/j.cub.2005.02.027.
16. Xu Y, Wang J, Qiu M, Xu L, Li M, Jiang F, et al. Upregulation of the long noncoding RNA TUG1 promotes proliferation and migration of esophageal squamous cell carcinoma. Tumour Biol. 2014. doi:10.1007/s13277-014-2763-6.
17. Zhang EB, Yin DD, Sun M, Kong R, Liu XH, You LH, et al. P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression. Cell Death Dis. 2014;5:e1243. doi:10.1038/cddis.2014.201.
18. Liu Y, Yang S, Zhang X. WITHDRAWN: down-regulation of long non-coding RNA TUG1 suppresses melanoma cell proliferation and induces apoptosis via up-regulating microRNA-9. Biochem Biophys Res Commun. 2013. doi:10.1016/j.bbrc.2013.09.050.
19. Zhang Q, Geng PL, Yin P, Wang XL, Jia JP, Yao J. Down-regulation of long non-coding RNA TUG1 inhibits osteosarcoma cell proliferation and promotes apoptosis. Asian Pac J Cancer Prev. 2013;14(4):2311–5.
20. Greiner M, Pfeiffer D, Smith RD. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev Vet Med. 2000;45(1–2):23–41.
21. Ma L, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. RNA Biol. 2013;10(6):925–33. doi:10.4161/rna.24604.
22. Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 2009;23(13):1494–504. doi:10.1101/gad.1800909.
23. Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene. 2013;32(13):1616–25. doi:10.1038/onc.2012.193.
24. Qi P, Xu MD, Ni SJ, Huang D, Wei P, Tan C, et al. Low expression of LOC285194 is associated with poor prognosis in colorectal cancer. J Transl Med. 2013;11:122. doi:10.1186/1479-5876-11-122.
25. Nagarajan R, Kamruzzaman A, Ness KK, Marchese VG, Sklar C, Mertens A, et al. Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the childhood cancer survivor study. Cancer. 2011;117(3):625–34. doi:10.1002/cncr.25446.
26. Wang Y, Yao J, Meng H, Yu Z, Wang Z, Yuan X, et al. A novel long non-coding RNA, hypoxia-inducible factor-2alpha promoter upstream transcript, functions as an inhibitor of osteosarcoma stem cells in vitro. Mol Med Rep. 2015;11(4):2534–40. doi:10.3892/mmr.2014.3024.
27. Dong Y, Liang G, Yuan B, Yang C, Gao R, Zhou X. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway. Tumour Biol. 2014. doi:10.1007/s13277-014-2631-4.
28. Chan LH, Wang W, Yeung W, Deng Y, Yuan P, Mak KK. Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression. Oncogene. 2014;33(40):4857–66. doi:10.1038/onc.2013.433.
29. Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011;25(18):1915–27. doi:10.1101/gad.17446611.
30. Karakiewicz PI, Briganti A, Chun FK, Trinh QD, Perrotte P, Ficarra V, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol. 2007;25(11):1316–22. doi:10.1200/JCO.2006.06.1218.
31. Wierda WG, O’Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109(11):4679–85. doi:10.1182/blood-2005-12-051458.
32. Deng Q, He B, Liu X, Yue J, Ying H, Pan Y, et al. Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model. J Transl Med. 2015;13(1):409. doi:10.1186/s12967-015-0409-0.
33. Sternberg CN. Are nomograms better than currently available stage groupings for bladder cancer? J Clin Oncol. 2006;24(24):3819–20. doi:10.1200/JCO.2006.07.1290.
34. Touijer K, Scardino PT. Nomograms for staging, prognosis, and predicting treatment outcomes. Cancer. 2009;115(13 Suppl):3107–11. doi:10.1002/cncr.24352.
35. Isin M, Ozgur E, Cetin G, Erten N, Aktan M, Gezer U, et al. Investigation of circulating lncRNAs in B-cell neoplasms. Clin Chim Acta. 2014;431:255–9. doi:10.1016/j.cca.2014.02.010.
36. Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer. 2013;49(13):2949–59. doi:10.1016/j.ejca.2013.04.026.